Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Published on 14/06/2025 at 01:46

Reuters

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Evolus, Inc.

Evolus, Inc. Partners with Symatese to Commence Distribution of Nuceiva	09/07	CI
Evolus Partners With Symatese to Distribute Nuceiva in France	09/07	MT
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)	14/06	RE
Evolus, Inc. Announces Albert White III to Serve on its Audit Committee, Effective June 5, 2025	07/06	CI
Evolus CFO Sandra Beaver Resigns	28/05	MT
Evolus Announces Departure Of Its Chief Financial Officer	28/05	RE
Evolus, Inc. Announces Resignation of Sandra Beaver as Chief Financial Officer, Effective June 13, 2025	28/05	CI
Evolus Announces Publication of U.S. Pivotal Study for Evolysse Form and Evolysse Smooth Injectable Hyaluronic Acid Gels	22/05	CI
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)	17/05	RE
Evolus, Inc., Q1 2025 Earnings Call, May 07, 2025	08/05
Evolus, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	08/05	CI
Evolus, Inc. Reaffirms Earnings Guidance for the Full Year 2025	08/05	CI
BioPharma Credit Receives $30 Million Partial Prepayment From BioCryst	06/05	RE
Evolus Inc - Enters New $250 Million Credit Facility With Pharmakon Advisors, Replacing Exisiting $125 Million Credit Agreement	06/05	RE
Evolus, Inc. Enters an Amended and Restated Credit Facility	06/05	CI
BTIG Initiates Evolus at Buy With $21 Price Target	17/04	MT
Evolus, Inc. Announces Commercial Launch of Evolysse	16/04	CI
Evolus Launches "Drop the F Word" Campaign in Advance of the Commercial Launch of Evolysse?? Injectable Hyaluronic Acid Gels	15/04	CI
Evolus reports inducement grants under Nasdaq listing rule 5635(C)(4)	22/03	RE
Evolus Insider Sold Shares Worth $1,370,249, According to a Recent SEC Filing	21/03	MT
Evolus, Inc. Presents at Barclays 27th Annual Global Healthcare Conference 2025, Mar-12-2025 03:30 PM	13/03
Top Premarket Decliners	11/03	MT
Evolus Q4 Net Loss Narrows, Revenue Rises; Issues Guidance	05/03	MT
Evolus, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	05/03	CI
Evolus, Inc., Q4 2024 Earnings Call, Mar 04, 2025	05/03